26.73
0.73 (2.81%)
| Previous Close | 26.00 |
| Open | 26.00 |
| Volume | 1,008,185 |
| Avg. Volume (3M) | 1,209,346 |
| Market Cap | 1,775,046,912 |
| Price / Sales | 296.30 |
| Price / Book | 2.62 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -9,027.19% |
| Diluted EPS (TTM) | -2.70 |
| Quarterly Revenue Growth (YOY) | 345.50% |
| Total Debt/Equity (MRQ) | 0.49% |
| Current Ratio (MRQ) | 21.67 |
| Operating Cash Flow (TTM) | -171.51 M |
| Levered Free Cash Flow (TTM) | -101.09 M |
| Return on Assets (TTM) | -16.88% |
| Return on Equity (TTM) | -23.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Celldex Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | 1.25 |
|
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.32% |
| % Held by Institutions | 113.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eventide Asset Management, Llc | 30 Jun 2025 | 1,356,186 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (Canaccord Genuity, 131.95%) | Buy |
| Median | 45.00 (68.35%) | |
| Low | 25.00 (Barclays, -6.47%) | Sell |
| Average | 43.83 (63.97%) | |
| Total | 5 Buy, 1 Sell | |
| Avg. Price @ Call | 23.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 21 Oct 2025 | 48.00 (79.57%) | Buy | 27.91 |
| Barclays | 13 Oct 2025 | 25.00 (-6.47%) | Sell | 27.13 |
| Canaccord Genuity | 17 Sep 2025 | 62.00 (131.95%) | Buy | 24.46 |
| 20 Aug 2025 | 62.00 (131.95%) | Buy | 20.89 | |
| Citigroup | 20 Aug 2025 | 48.00 (79.57%) | Buy | 20.89 |
| HC Wainwright & Co. | 20 Aug 2025 | 42.00 (57.13%) | Buy | 20.89 |
| Wells Fargo | 20 Aug 2025 | 38.00 (42.16%) | Buy | 20.89 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Oct 2025 | Announcement | Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition |
| 17 Sep 2025 | Announcement | Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 |
| 09 Sep 2025 | Announcement | Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference |
| 19 Aug 2025 | Announcement | Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) |
| 07 Aug 2025 | Announcement | Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |